Hepatocellular carcinoma (HCC) – Daneng Li, MD and Robert Figlin, MD, discuss clinical highlights from ASCO 2019

Hepatocellular carcinoma (HCC) – Daneng Li, MD and Robert Figlin, MD, discuss clinical highlights from ASCO 2019

Tuesday July 2, 2019

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, discuss HCC highlights from ASCO 2019.

Featured Videos

Nevena Damjanov, MD, on impressions of the study combining cabozantinib with checkpoint inhibitors in advanced HCC patients

Ahmed Kaseb, MD, on the differentiation of levatinib vs cabozantinib for HCC treatment

Ahmed Kaseb, MD, explains the role of immunotherapy in neo-adjuvant treatment of resectable HCC